A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

September 30, 2031

Study Completion Date

September 30, 2033

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG

Blinatumomab

Given by IV

DRUG

Mini-CVD

Given by IV

DRUG

MTX/ARA-C

Given by IV

Trial Locations (1)

The University of Texas M. D. Anderson Cancer Center, Houston